AKT1 and prostate carcinoma: Increasing evidence indicates that the PI3K/Akt/mTOR pathway may directly regulate the expression and activation of AR [46], which necessitates a dual inhibition of both the AR and PI3K/Akt pathways for a durable control of prostate cancer.